Bruker(BRKR)
Search documents
Bruker (BRKR) Launches neofleX MALDI-TOF/TOF MSI System
ZACKS· 2024-06-04 14:31
Bruker Corporation (BRKR) recently announced the launch of the neofleX Imaging Profiler for mass spectrometry-based tissue imaging at the 72nd ASMS meeting. The novel, high-performance MALDITOF/TOF system enables facile OME-TIFF file output via the new SCiLS Scope software and conveniently fits on a benchtop. The latest development is expected to significantly boost the company's Life Sciences Mass Spectrometry division within the Bruker Scientific Instruments ("BSI") CALID segment. About neofleX The neofle ...
Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference
Newsfilter· 2024-05-30 13:15
ZURICH, Switzerland and NEWTON, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, has announced the company's attendance at the American Society for Mass Spectrometry (ASMS) Annual Conference from June 2nd to June 6th in Anaheim, CA, where the company will launch Spectronaut 19 and present major scientific and technological advances for its proprietary proteomics research software, services, and data insights solutions. Biogn ...
Bruker (BRKR) Gains Market Share on Innovation Amid Macro Woes
zacks.com· 2024-05-22 16:16
Bruker Corporation's (BRKR) strong growth reflects its fundamental commitment to innovate high-value solutions, and the ongoing portfolio transformation. However, macroeconomic issues dent profit. The stock carries a Zacks Rank #3 (Hold) currently. Bruker's CALID business has been gaining from the strong demand for differentiated instruments, particularly in life science mass spectrometry proteomics solutions and optics spectroscopy and microscopy instruments. Bruker's flagship timsTOF platform is a key dri ...
2 Instruments Stocks to Watch From a Prospering Industry
Zacks Investment Research· 2024-05-14 15:01
The Zacks Instruments - Scientific industry is benefiting from increasing healthcare spending, driven by aging demography, and continued innovation in the pharma and life sciences end-markets. Higher demand for generic drugs and biosimilars is driving growth for scientific tool and apparatus providers. Industry participants like Mettler-Toledo International (MTD) and Bruker (BRKR) are gaining from the growing testing needs of newer biological drugs. Increased scrutiny of per and polyfluoroalkyl substances i ...
Investing in Bruker (BRKR)? Don't Miss Assessing Its International Revenue Trends
Zacks Investment Research· 2024-05-13 14:20
Have you evaluated the performance of Bruker's (BRKR) international operations for the quarter ending March 2024? Given the extensive global presence of this scientific equipment maker, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors must u ...
Bruker(BRKR) - 2024 Q1 - Quarterly Report
2024-05-10 19:29
Equity in Income of Unconsolidated Investees, net of tax Equity in Income of Unconsolidated Investees, net of tax represents the Company's proportional share of the earnings or losses as reported by equity-method investees. Net Income Attributable to Noncontrolling Interests The net income attributable to noncontrolling interests represented the minority shareholders' proportionate share of the net income recorded by our majority-owned subsidiaries. 35 Table of Contents LIQUIDITY AND CAPITAL RESOURCES 31 Op ...
Down -22.53% in 4 Weeks, Here's Why Bruker (BRKR) Looks Ripe for a Turnaround
Zacks Investment Research· 2024-05-06 14:36
Bruker (BRKR) has been on a downward spiral lately with significant selling pressure. After declining 22.5% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is ...
Bruker(BRKR) - 2024 Q1 - Earnings Call Transcript
2024-05-02 20:00
Company Participants Conference Call Participants Operator Thank you, and good morning, everybody. I would like to welcome everyone to Bruker Corporation's first quarter 2024 earnings conference call. My name is Justin Ward, and I am Bruker's Senior Director of Investor Relations and Corporate Development. Joining me on today's call are Frank Laukien, our President and CEO, and Gerald Herman, our Executive Vice President and CFO. In addition to the earnings release we issued earlier today, during today's co ...
Bruker(BRKR) - 2024 Q1 - Earnings Call Presentation
2024-05-02 16:18
Q1 2024 Earnings Presentation May 2, 2024 BRUKER CORPORATION (NASDAQ: BRKR) Frank H. Laukien, President & Chief Executive Officer Gerald Herman, Executive Vice President & Chief Financial Officer Justin Ward, Senior Director, Investor Relations & Corporate Development Safe Harbor Statement © 2022 Bruker + -Bruker | | Confidential- © 2023 Bruker | | Q1 2024 Business Update Q1 2024 BUSINESS UPDATE Margin Performance Impacted by Tough Comparison, Acquisitions and FX Reconciliations of non-GAAP to GAAP financia ...
Bruker (BRKR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research· 2024-05-02 15:31
Bruker (BRKR) reported $721.7 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 5.3%. EPS of $0.53 for the same period compares to $0.64 a year ago.The reported revenue represents a surprise of -0.30% over the Zacks Consensus Estimate of $723.84 million. With the consensus EPS estimate being $0.46, the EPS surprise was +15.22%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ex ...